Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The latest news and opinion from Nature on the novel coronavirus and COVID-19.
Sign up for the free Nature Briefing to get the latest coronavirus news in your inbox, and an essential round-up of other science news, opinion and analysis.
Find research papers related to the coronavirus here.
The Pfizer–BioNTech vaccine has passed safety and efficacy tests — but researchers still have many questions about how this and other vaccines will perform as they’re rolled out to millions of people.
Scientists welcome the first compelling evidence that a vaccine can prevent COVID-19. But questions remain about how much protection it offers, to whom and for how long.
The science supports that face coverings are saving lives during the coronavirus pandemic, and yet the debate trundles on. How much evidence is enough?
COVID-19 poses the greatest threat to older people, but vaccines often don’t work well in this group. Scientists hope drugs that rejuvenate the immune system will help.
Researchers warn that official figures underestimate the pandemic’s real death toll, which could more than triple if the virus is allowed to spread unchecked.
The scenarios foresaw leaky travel bans, a scramble for vaccines and disputes between state and federal leaders, but none could anticipate the current levels of dysfunction in the United States.
Governments are starting to change policies amid concerns that tiny droplets can carry SARS-CoV-2. And after months of denying the importance of this, the World Health Organization is reconsidering its stance.
A study that suggested using hydroxychloroquine — a malaria drug — to treat people with COVID-19 could be dangerous has slowed clinical trials, but the study itself has also been questioned.
Near-real-time data on carbon emissions reveal the sectors, countries and events that had the most impact, but it is unclear how long the dip will last.
Scientists are piecing together how SARS-CoV-2 operates, where it came from and what it might do next — but pressing questions remain about the source of COVID-19.
Despite conflicting studies, results from largest trial yet show the antiviral speeds up recovery, putting it on track to become a standard of care in the United States.
With politicians touting the potential benefits of malaria drugs to fight COVID-19, some people are turning away from clinical trials of other therapies.
Researchers everywhere must continue to press their lawmakers to act now and challenge US President Donald Trump’s undermining of the global health agency.
Nature examines how viral diagnostic tests work, why testing has varied around the world and the CRISPR-based tests under development to fight COVID-19.